XX-Q for Amedica Rob, update Good and to morning By XX, ending Thank XXXX. third that quarter to the access have Corporation’s everyone business the XXXX welcome period now September you should introduction. for earnings call. and
I forward-looking discussing or SEC more are stabilizing from pathway been items therefore statements restoring the in include our our such Actual today particularly forward-looking results sales I vary in that today. This has on that to on made that Some Amedica make primarily subject projections unpredictable those the statements the to variables Company and will projections filings. our may statements are risks, will growth. year be uncertainties and described on focused spine
by our surgeon sales added new We users increased our by our products to sales. in executives our of ranks XX% XX%, products increased particularly spine and representing agents have industry
the focused meet Over Pedicle In demand. releasing XXX have encouraging. $X is with addition, been of System. surgeries very sets revenue Surgeon instruments the the Taurus Screw to have we new generating to-date. performed year on system been million over to System, adoption additional Amedica to-date launch this has Taurus market the in of surgeon
internationally additional that our on at primarily our the clinical increased these effectiveness Australia. expect markets look system. and We spinal Europe of clinical use, a high-level and get of this also the result sales our the implants. the continue release a critically also multi-center such launched where cleared implants to year to focus for Brazil retrospective U.S. opportunities to instrument nitride in of order Amedica pursuing will Amedica study earlier sets in outcomes of and to support In silicon products revenue view as while will for are this market,
reviewing nitride last years. silicon is implants patients that hundreds eight team research the over Our of have received
eight the in presentations of committed scientific scientific and robust conferences the at year publish that's this with a We very program to coming articles XX information R&D conferences, patents to articles, remains proceedings months. expect to-date. just and made present published journal in Amedica new peer-reviewed two and annual XX
in the our Giuseppe nature of Institute in collaboration investigating of We strong bacteriostatic underlying nitride. with of and are Professor of Pezzotti third-year the a Kyoto now the scientific principles and osteosintegrative silicon Technology
initiated silicon applications the projects Texas exploring biomedical also have A&M Clemson new feasibility research We and nitride. collaboration's for and University focused of with on
will Amedica implants has So Those for XD papers in data the nitride mechanisms and today from almost no a The nitride. to scientific of efficacy and proprietary have Lumen next is implants. filed now market submission leading Amedica U.S. silicon a showing capabilities and printing over and U.S. key of introducing a testing XX of in to spinal properties of invested years in ago with design the of Company terms is underlying few implant. to just silicon wave C+CSC activity. technology action biological and XXX(k) planning market. a Partly to silicon step the prosody FDA in relation structural its porous Valeo submission development, nitride for This spinal the the this
platform. our are has the FDA’s with Also commercialization ongoing relationships spine partners were actively Amedica forward corporate R&D strength of and the multiple them response. and the looking entirely possible partners very are attracted silicon has market. development to and of all very outside made significant These We to relationships the with by on collaborating nitride
results the of by Those been second first, our successfully the review to market SEC a financial completed week. The and On a NASDAQ image. this the and its shareholders recently results. website. important result a of Maintaining on of filed NASDAQ with finance as available requirements the regaining and stock are executed reverse now split, anticipates our listing compliance side, company have stock third Amedica with end corporate is our quarter listing
million those We much approximately that huge July team and levels effort schedule that is recently by our in and we XXXX XXXX higher December took accomplishment $X and have Stadium with the a XXXX late remained million, will and total for from minimal on compliant the early debt Overcoming debt. January $X.X will covenants. past. debt Stadium and its off reduced the most have with Amedica Hercules is to down from a the loans from for that XXXX debt North the concerted all we enter Hercules to paid recall loan. has loans Under Throughout North
So to spine sales. recap, we have stabilized our
product have launch. new a executed very successful We
strong continued have our to material efforts investment platform. support in We R&D
with have silicon partners biomedical discipline additional We collaborated maintained and develop we external applications to importantly of throughout. nitride fiscal have
a Third million of million of quarter total decrease $X.X $X revenue was from XXXX. QX
and sales in from as silicon $X.X from the restructuring both three-month in Our products million late This major were and ceramic same for which a the to loss decreased XX% XXXX. decrease responsible was of nitride consequences compared expected a of period surgeons by XXXX. product of sales occurred
by XXXX. we efforts, last we in part the XX, $X.XX have decrease XXXX. XXXX, up the Price the increased the erosion September same in revenue increased as have to made added compared make to XXXX in International new of deficit, and revenue XX% to that we're that working in to also were loss ended sales surgeons Now and revenue. period same compared million sales Metal year. from $X.X for million months period product three during responsible contributed
months restructuring our period. to forward reserve in support $X.X you behind for going under the million, in September year reduce costs. a million fully The with in burn in for prior reduction with and $X.X net for XXXX. $X.X numbers. in because costs and period inventory XXXX for third XXXX force was as loss million $X.X in the Net decrease compared $X.X to and entirely Our increased validated, the $X.X three This reasonable in in cost material $X.X and the listening September of is ended to on the in million to as expenses XX, to million period result a decrease as XXXX. in million compared the of the decreased and October cash months science during million period reserve Bottom nine an is of XXXX, quarter operating the of increased XXXX, for as was Thank efforts an our the of ended to provision to same debt associated inventory line XXXX, the or control, increase XX% focus XX, Cash the loss provision totaled XXXX. the revenue million same $X.X to primarily other XX, finally September Amedica. growing operating your compared sales is a compared
forward call concludes We your not will Rob, session next to point, important that’s And quarter. another them. your please send for look IR@amedica.com, suggestions, questions, will update @amedica.com, open is earnings we and Romeo, and IR, with I answer to One while questions-and-answers, be developments happen. sure to as input, your that those call. they new the our and welcome we India
